Research

Hormonal

Tirzepatide treatment produces similar improvements in glycemic control (HbA1c) and body weight in patients with early-onset type 2 diabetes (diagnosed before age 40) compared to those with later-onset type 2 diabetes.

If you were diagnosed with type 2 diabetes before age 40, you may have heard that your condition is harder to treat. This analysis of major clinical trials shows that the medication tirzepatide works just as well for you as it does for older patients, significantly lowering blood sugar and body weight. You should discuss this option with your doctor, as it addresses the specific metabolic challenges often seen in early-onset diabetes.

GoodSupportsHIGH confidence
In this post hoc analysis, similar improvements in HbA1c, BW and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis.
Philip Zeitler et al. · Diabetes Care · 2024

Why this rating

Post hoc analysis of Phase 3 randomized controlled trials (SURPASS program) provides high-quality evidence, though the post hoc nature limits causal inference regarding the interaction term compared to pre-specified endpoints.

Source

Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program

Philip Zeitler et al. · Diabetes Care · 2024

DOI 10.2337/dc23-2356

rct · n=3792Cited 11×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →